The listing of Symbiotec Pharmalab was well below GMP expectations, which had indicated a listing gain of around 18-19 per cent for IPO investors.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.